Basit öğe kaydını göster

dc.contributor.authorKunchok, A.
dc.contributor.authorMalpas, C.
dc.contributor.authorHorakova, D.
dc.contributor.authorHavrdova, E.
dc.contributor.authorAlroughani, R.
dc.contributor.authorTerzi, M.
dc.contributor.authorAltintas, A.
dc.date.accessioned2020-06-21T13:06:37Z
dc.date.available2020-06-21T13:06:37Z
dc.date.issued2018
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.urihttps://hdl.handle.net/20.500.12712/11390
dc.description34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- OCT 10-12, 2018 -- Berlin, GERMANYen_US
dc.descriptionAltintas, Ayse/0000-0002-8524-5087; McCombe, Pamela/0000-0003-2704-8517; Lugaresi, Alessandra/0000-0003-2902-5589; Turkoglu, Recai/0000-0001-9724-851X; Laureys, Guy/0000-0002-1708-4373en_US
dc.descriptionWOS: 000446861401327en_US
dc.description.abstracten_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipBiogenBiogen; Charles University in Prague [PRVOUK-P26/LF1/4]; Czech Minsitry of Education [Q27/LF1]; Czech Ministry of HealthMinistry of Health, Czech Republic [NT13237-4/2012]; NovartisNovartis; Bayer-ScheringBayer AG; MerckMerck & Company; Teva; Almirall; Bayer ScheringBayer AG; Sanofi-AventisSanofi-Aventis; Sanofi AventisSanofi-Aventis; GenzymeGenzyme Corporation; Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche; Biogen IdecBiogen; Sanofi Genzyme; BayerBayer AG; SanofiSanofi-Aventis; Biogen - Gen Pharma; RocheRoche Holding; Sanofi-Genzyme; Teva Neurosciences; Mitsubishi; ONO Pharmaceuticals; Fondazione Italiana Sclerosi Multipla (FISM)Fondazione Italiana Sclerosi Multipla (FISM); Guthy-Jackson Charitable Foundation; National Multiple Sclerosis SocietyNational Multiple Sclerosis Societyen_US
dc.description.sponsorshipAmy Kunchok received research support from Biogen.; Dana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva and Novartis, as well as support for research activities from Biogen and research grants from Charles University in Prague [PRVOUK-P26/LF1/4], Czech Minsitry of Education [PROGRES Q27/LF1] and Czech Ministry of Health [NT13237-4/2012].; Murat Terzi received travel grants from Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.; Franco Granella received research grant from Biogen, served on scientific advisory boards for Biogen, Novartis, Merck, and Sanofi-Aventis and received funding for travel and speaker honoraria from Biogen, Merck, Sanofi-Aventis, and Almirall.; Tunde Csepany received speaker honoraria/conference travel support from Bayer Schering, Biogen, Merck, Novartis and Teva. Roberto Bergamaschi received speaker honoraria from Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva; research grants from Bayer Schering, Biogen, Merck, Novartis, Sanofi-Aventis, Teva; congress and travel/ accommodation expense compensations by Almirall, Bayer Schering, Biogen, Genzyme, Merck, Novartis, Sanofi-Aventis, Teva.; Eugenio Pucci served on scientific advisory boards for Merck, Genzyme and Biogen; he has received honoraria and travel grants from Sanofi Aventis, Novartis, Biogen, Merck, Genzyme and Teva; he has received travel grants and equipment from "Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche".; Patrizia Sola served on scientific advisory boards for Biogen Idec and TEVA, she has received funding for travel and speaker honoraria from Biogen Idec, Merck, Teva, Sanofi Genzyme, Novartis and Bayer and research grants for her Institution from Bayer, Biogen, Merck, Novartis, Sanofi, Teva.; Ayse Altintas received personal fees and speaker honoraria from Teva, Merck, Biogen - Gen Pharma, Roche, Novartis, Bayer, Sanofi-Genzyme; received travel and registration grants from Merck, Biogen - Gen Pharma, Roche, Sanofi-Genzyme and Bayer. Aysun Soysal did not declare any competing interests.; Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals.; Alessandra Lugaresi is a Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Roche, Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institution received research grants from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM).; Ilya Kister served on scientific advisory board for Biogen and received research support from Guthy-Jackson Charitable Foundation, National Multiple Sclerosis Society, Biogen,, and Novartis.en_US
dc.language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleClinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorderen_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume24en_US
dc.identifier.startpage535en_US
dc.identifier.endpage537en_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster